At Kineticos, our senior team consists of life sciences industry professionals with decades of combined experience and highly-diversified backgrounds. With a wealth of knowledge gained from this extensive life science experience, Kineticos delivers significant value to a range of clients seeking trusted strategy consulting services. Below, you will find information and details about the backgrounds, education, and industry experience of our leadership team members.
Mr. Maingi founded Kineticos Life Sciences in 2007 and develops long-term and day-to-day execution strategies.
In addition to serving as CEO of Kineticos, Mr. Maingi is as a Board Observer for Locus BioSciences, a CRISPR gene editing start-up. Mr. Maingi also served on the Board of Directors at Gallus Biopharmaceutical, a biopharmaceutical CMO, and on the Advisory Boards of Novolipid and Enci Therapeutics, two pre-clinical oncology biotechnology start-ups. Mr. Maingi is currently on the Board of Directors at Prevention Partners, a Chapel Hill, NC based non-profit. In addition, Mr. Maingi is Adjunct Faculty at the UNC’s Kenan-Flagler School of Business.
Prior to founding Kineticos Life Sciences, Mr. Maingi was a senior executive at Cardinal Health/PTS and Sigma-Aldrich/Supelco. Mr. Maingi earned a BS in Chemistry from UNC, Chapel Hill and an MBA from Golden Gate University.
Mr. Maingi’s Areas of Expertise:
- Corporate Strategy and Execution
- Research and Innovation
- Business and Corporate Development
- Process Improvement / Change Management
Mr. Hampton brings over 12 years of operational and commercial of experience to the firm.
As Chief Commercial Officer, Mr. Hampton is responsible for driving and managing all sales and marketing activities such as business development, thought leadership, branding/awareness, and demand generation. Prior to being appointed CCO, Mr. Hampton served as Managing Director of the Biopharmaceutical practice at Kineticos where he led both commercial and operational functions for the firm’s top growing practice. Mr. Hampton, who has been with Kineticos since 2013, started his tenure in finance and operational focused roles but transitioned into marketing in 2015. Soon after, he was named Vice President of Marketing and played an integral role in establishing thought leadership and lead generation programs that are now the core of Kineticos’ marketing function.
Mr. Hampton earned his BS degree in Business Management with a Finance concentration from North Carolina State University.
Mr. Hampton’s Areas of Expertise:
- Corporate Development
- Business Development and Licensing
- Key Opinion Leader Engagement
- Sales and Marketing
Mr. Buckanavage adds over 30 years of commercial experience in the pharmaceutical and biotech industry having successfully launched products in the US, Europe, and Japan. Most recently, Steve held senior commercial positions at Celyad, assisting the Belgium based cell & gene therapy company through a successful US IPO, establishing US operations in Boston, staffing key roles and running operations. Prior to joining Celyad, Mr. Buckanavage was the VP of Commercial Strategy at GSK’s Cancer Immunotherapy Business Unit where he was responsible for the commercial strategy for the antigen specific cancer immunotherapy portfolio. Prior to that, Steve spent over 25 years at AstraZeneca in various roles. He was the US Commercial Head for franchises such as cardiovascular, anesthesia, and infectious disease having launched brands in all three categories. His time at AstraZeneca also included serving as the Global VP of Emerging Oncology responsible for a portfolio of small molecule and biologic assets.
Mr. Buckanavage’s Areas of Expertise:
- Commercial Strategy
- Portfolio Planning
- Corporate Development
Eric Nelson, PhD
Dr. Nelson is a broadly-experienced therapeutics product development strategy and pharmaceutical partnerships professional. In the last 15 years, he has delivered consulting projects to over 300 clients in Europe, Asia, and the US. He has also been interim head of business development for several CRO and early-stage biotech companies. Dr. Nelson’s previous employments were at Pfizer/Wyeth, Becton Dickinson, Elan, Advinus Therapeutics, Tranzyme, and the NIH. He has worked with many cross-functional teams to develop product development strategies and to close on over 50 biotech to pharma drug development partnerships worth over $1B. As a member of biotech management teams, Dr. Nelson has helped build several biotechnology companies from seed stage through successful IPO or acquisition exits. His therapeutic areas of expertise include oncology, respiratory, rare/genetic diseases, immunology, neurology, and anti-infectives. By therapeutic modality in addition to small molecules, he is an expert in the assessment and development of therapeutic Mabs, vaccines, gene therapy/RNAi, and stem cell/Car-T/cellular therapies.
Dr. Nelson earned his Ph.D. at The Johns Hopkins School of Medicine doing research on the biochemical mechanisms of topoisomerase chemotherapeutic drugs. His post-doctoral research in the biochemistry department of Harvard university was on the genetics of DNA replication enzymes.
Dr. Nelson’s Areas of Expertise:
- Business Development and Licensing
Alex Stojanovic, PhD
Dr. Stojanovic brings 15 years of commercial strategy, marketing, and business development experience in the life science industry. Concurrently, he serves as Partner at The Naissos Group, a boutique creative consultancy helping life science companies with multichannel marketing strategy and execution via traditional and digital channels. His background spans consulting and industry roles with more than 50 companies, across 20 countries, with a particular focus in CNS, including fields such as neuropathic pain, neurodegenerative disease, epilepsy, and anesthesia. Prior to joining Kineticos, Dr. Stojanovic served as Vice President of Business Development and Commercial Operations at Phosphagenics, as well as Head of New Products Marketing at Grunenthal, where he was responsible for guiding the commercial development of pipeline entities from phase 1 to phase 3.
Earlier in his career, Dr. Stojanovic spent 6 years with ZS Associates, providing consulting services to biotech and pharmaceutical companies across corporate and commercial strategy.
Dr. Stojanovic’s Areas of Expertise
- Portfolio Optimization
- Commercial Planning
- Drug Delivery
Mr. Montgomery has successfully launched and operationalized real world data-based specialty healthcare businesses to optimally inform market, clinical and financial decision-making for pharmaceutical researchers, providers and payers. Most recently, Mr. Montgomery was Vice President, Analytics for Integra Connect, an emerging healthcare services company focused on expanding care access through high value provider technology and population health analytics in the oncology and urology space. Previously, Mr. Montgomery was Director, Healthcare Analytics for Cardinal Health Specialty Solutions, building and managing Cardinal’s Healthcare Analytics team, including healthcare economics, outcomes research and commercial insights to manufacturers, payers and providers. Mr. Montgomery is an advisory board member of Lantern Pharma and previous board member of the Coalition on Donation (United Network for Organ Sharing).
Mr. Montgomery received a BS in Microbiology from L.S.U. and an MPH from Johns Hopkins Bloomberg School of Public Health.
Mr. Montgomery’s Areas of Expertise:
- Infectious Diseases
- Real World Evidence
- Molecular Diagnostics
Dr. Tom Zietlow
Dr. Zietlow has nearly 30 years of diverse experience in the pharmaceutical, manufacturing and diagnostics industries, across R&D, product commercialization, brand marketing and management. Tom negotiated and managed joint international ventures in Europe and Asia, including projects and marketing programs in diverse industries for Eastman Kodak, Corpex Technologies, Diagnology, Cardinal Health in the Pharmaceutical Services (PTS) business and Becton Dickinson. Most recently, Tom specialized in the emerging field of personalized medicine, supporting pharmaceutical and diagnostic companies in the commercialization of companion diagnostics as President of Diaceutics.
He received his Ph.D. in chemistry from the California Institute of Technology and an MBA from the Kenan-Flagler School of Business at UNC – Chapel Hill.
Dr. Zietlow’s Areas of Expertise:
- Precision Medicine
- Strategic Planning
Mr. Kopp has 30 years of experience in the global pharmaceutical, biotechnology and healthcare sectors. Michael previous built and ran commercial operations for Mylan’s US hospital business. He subsequently led business development for Mylan’s North American branded and generics businesses, had P&L responsibility for the ex-US EpiPen® franchise, and was accountable for all product selection, portfolio management, alliance management activities. Michael has also held senior leadership roles with Xellia Pharmaceuticals (Novo A/S) Cardinal Health, McKesson, Teva and Sandoz, and previously served on the Board of Directors for DCAT.
His experience spans the pharmaceutical continuum – from API synthesis through patient point of dispensing – and includes nearly all commercial channels and dose forms. Mr. Kopp is a life member of Mensa.
Mr. Kopp’s Areas of Expertise:
- Portfolio Management
- Alliance Management
Mr. Osterman, Senior Vice President of Kineticos’ Biopharmaceutical Practice, adds more than 25 years of experience in the biopharmaceutical industry to the team.
Mr. Osterman held roles in sales, clinical, and marketing at GlaxoSmithKline before moving to Johnson & Johnson, where he launched their stem cell internal venture and was responsible for the cardiovascular, pulmonary, metabolic, and mimetibody therapeutic areas in the Global Biologic Strategic Marketing. Mr. Osterman then served as Senior Vice President responsible for commercial operations and business development at Discovery Labs before accepting a position as Vice President of Global Marketing at Solstice Neurosciences. Immediately prior to joining Kineticos, he founded the Osterman Strategy Group, a boutique management consulting firm, where he worked with large and emerging biopharmaceutical companies to help solve their most challenging business issues.
Mr. Osterman earned a dual BA in Business Management and Economics from North Carolina State University.
Mr. Osterman’s Areas of Expertise:
- Global Strategic Marketing
- New Business Development
- Merger and Acquisition Strategy
- Organizational and Leadership Development
Mr. Dupere brings 30 years of experience in the biopharmaceutical industry to the Kineticos team. He spent 10 years immersed in formative training across core disciplines including clinical research, regulatory affairs, project, communications, and product management at both medical device (CTL, Inc.) and pharmaceuticals (Burroughs Wellcome Co.). He then started ATOM, Inc., a boutique consultancy focused on helping companies–including Lilly, Genentech, Sanofi and others—project manage the commercial launch their first oncology product. Mr. Dupere progressed to start new business units as Vice President of Business Development at LifeMetrix, retained consultant at US Oncology (Market Focus), and Sr. Vice President, Oncology Biopharmaceutical Solutions at Biologics, Inc. More recently, as COO for QOL Medical, he successfully re-positioned and built out an orphan disease company.
Mr. Dupere earned his BS in Public Health and MBA, both from the University of North Carolina at Chapel Hill.
Mr. Dupere’s Areas of Expertise:
- Product Opportunity Assessment
- Commercialization Strategy
- Out-sourcing Integration
- Patient Access and Optimization